Literature DB >> 30046637

A MIXED METHODS APPROACH TO TAILORING EVIDENCE-BASED GUIDANCE FOR ANTIBIOTIC STEWARDSHIP TO ONE MEDICAL SYSTEM.

Emily S Patterson1, Courtney M Dewart2, Kurt Stevenson2, Awa Mbodj2, Mark Lustberg2, Erinn M Hade2, Courtney Hebert2.   

Abstract

Our objective is to operationalize a novel antibiotic advisor, called the personalized weighted incidence syndromic combination antibiogram (pWISCA), intended to help physicians with initial antibiotic choice in hospitals. Clinical decision support tools are a promising technology for providing evidence-based guidance that incorporates data about patients from electronic health records. Nevertheless, congruence with policies and procedures and local experts' opinions, as well as taking into account local resistance data for the medical center's patient population, is needed when selecting and ordering the antibiotic medication options provided by pWISCA. This paper presents findings from applying a mixed methods approach to identify and prioritize antibiotic medications and associated contextual data to display in a CDS tailored to the local hospital. We discuss implications of these findings.

Entities:  

Year:  2018        PMID: 30046637      PMCID: PMC6056269          DOI: 10.1177/2327857918071053

Source DB:  PubMed          Journal:  Proc Int Symp Hum Factors Ergon Healthc        ISSN: 2327-8579


  8 in total

Review 1.  Research guidelines for the Delphi survey technique.

Authors:  F Hasson; S Keeney; H McKenna
Journal:  J Adv Nurs       Date:  2000-10       Impact factor: 3.187

2.  Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial.

Authors:  Mical Paul; Steen Andreassen; Evelina Tacconelli; Anders D Nielsen; Nadja Almanasreh; Uwe Frank; Roberto Cauda; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2006-09-23       Impact factor: 5.790

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

4.  Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention.

Authors:  Loria A Pollack; Arjun Srinivasan
Journal:  Clin Infect Dis       Date:  2014-10-15       Impact factor: 9.079

5.  An Algorithm Using Twelve Properties of Antibiotics to Find the Recommended Antibiotics, as in CPGs.

Authors:  R Tsopra; A Venot; C Duclos
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

6.  Database-driven computerized antibiotic decision support: novel use of expert antibiotic susceptibility rules embedded in a pathogen-antibiotic logic matrix.

Authors:  Charles J Mullett; John G Thomas
Journal:  AMIA Annu Symp Proc       Date:  2003

7.  Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit.

Authors:  Robert D Becher; J Jason Hoth; Jerry J Rebo; Jennifer L Kendall; Preston R Miller
Journal:  Surg Infect (Larchmt)       Date:  2012-12       Impact factor: 2.150

8.  Implementation of a Mobile Clinical Decision Support Application to Augment Local Antimicrobial Stewardship.

Authors:  Brian M Hoff; Diana C Ford; Dilek Ince; Erika J Ernst; Daniel J Livorsi; Brett H Heintz; Vincent Masse; Michael J Brownlee; Bradley A Ford
Journal:  J Pathol Inform       Date:  2018-04-02
  8 in total
  1 in total

1.  Prediction of Antibiotic Susceptibility for Urinary Tract Infection in a Hospital Setting.

Authors:  Courtney Hebert; Yuan Gao; Protiva Rahman; Courtney Dewart; Mark Lustberg; Preeti Pancholi; Kurt Stevenson; Nirav S Shah; Erinn M Hade
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.